CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.
CASI offers the following value drivers:
- Development of New Chemical Entities – ENMD-2076 for the treatment of multiple solid tumors.
- Acquisition of Approved Products – Commercialization in greater China, including China, Taiwan, Hong Kong, and Macau.
Market - Well-positioned to pursue significant and unprecedented market opportunities in China and worldwide.
Model - Compelling business model with important North America/China synergies and competitive advantage with efficiency and effectiveness for drug development and commercialization.
Product - A strong and growing product pipeline developed under dual models of acquisition and internal development.
Management - An experienced, motivated leadership team with a track record of accomplishment in both North America and China.
Finance - Strong cash position, backed by successful venture fund and smart money, under careful financial management with low burn rate.
Value Drivers - Significant defined near-term value drivers supporting long-term growth.
Annual Stockholders Meeting Notice and Proxy
June 2, 2016
Download proxy & meeting materials
Safe Harbor Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company’s Securities and Exchange Commission filings under “Risk Factors,” including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of ENMD-2076; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).